Aridis pharmaceuticals' covid mab ranks among the top 5 most potent covid-19 mabs evaluated by the coronavirus immunotherapeutics consortium (covic)

Los gatos, calif., july 26, 2021 /prnewswire/ -- aridis pharmaceuticals, inc. (nasdaq: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that animal efficacy data reported by the coronavirus immunotherapeutics consortium (covic) showed that the company's covid-19 monoclonal antibody (mab) ar-711, one of two mabs in the ar-712 cocktail, ranks among the top 5 most potent mabs that the covic consortium have studied to date.
ARDS Ratings Summary
ARDS Quant Ranking